Disc Medicine Inc是一家临床阶段的生物制药公司。该公司主要从事为患有严重血液病的患者发现、开发和商业化治疗方法。该公司正在建立一系列治疗候选药物,通过针对红细胞生物学的基本生物学途径,特别是血红素生物合成和铁稳态,专注于解决一系列血液病。该公司的产品线包括Bitopertin、DISC-0974和matriptase-2(TMPRSS6)。Bitopertin是甘氨酸转运蛋白 1 (GlyT1)的选择性抑制剂。DISC-0974是一种可注射的mAb,可抑制通过血幼素(HJV)发出的信号,HJV是一种铁调素表达所需的辅助受体。其开发口服matriptase-2 (TMPRSS6)抑制剂的临床前计划旨在增加hepcidin的内源性表达。
名称 | 标题 | 任期 | 年龄 |
|---|---|---|---|
| Donald William Nicholson | Executive Chairman | 2019 | 67 |
| John D. Quisel | CEO, President & Director | 2020 | 55 |
| Brian MacDonald | Founder & Chair of Scientific Advisory Board | 2023 | 65 |
| Kevin J. Bitterman | Independent Director | 2017 | 50 |
| William R. White | Independent Director | 2020 | 52 |
| Liam Ratcliffe | Independent Director | 2019 | 63 |
| Mark David Chin | Independent Director | 2021 | 44 |
| Mark Fleming | Member of Scientific Advisory Board | - | - |
| Tomas Ganz | Member of Scientific Advisory Board | 2020 | - |
| Elizabeta Nemeth | Member of Scientific Advisory Board | 2020 | - |
| Stefano Rivella | Member of Scientific Advisory Board | - | - |
| Uma Sinha | Member of Scientific Advisory Board | - | 68 |
| Georges Gemayel | Director | 2022 | 66 |
| Nadim Ahmed | Director | 2025 | 58 |